[Diferelin treatment of primary local and generalized cancer of the prostate].
Kolesnikov
G P
GP
Rusakov
I G
IG
Shaplygin
L V
LV
Voznesenskiĭ
S A
SA
Bystrov
A A
AA
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D013739:Testosterone; D017430:Prostate-Specific Antigen
Primenenie diferelina pri pervichno vyiavlennom mestno-rasprostranennom i generalizovannom rake predstatel'noĭ zhelezy.